Glycerophospholipid-driven lipid metabolic reprogramming as a common key mechanism in the progression of human primary hepatocellular carcinoma and cholangiocarcinoma.

Humans Cholangiocarcinoma / metabolism Carcinoma, Hepatocellular / metabolism Liver Neoplasms / metabolism Glycerophospholipids / metabolism Lipid Metabolism Male Middle Aged Female Bile Duct Neoplasms / metabolism Metabolomics / methods Disease Progression Phosphatidylcholines / metabolism Lysophosphatidylcholines / metabolism Aged Phospholipases A2 / metabolism Metabolic Reprogramming
CCA Glycerophospholipid metabolism HCC Metabolic reprogramming Phospholipase A2

Journal

Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696

Informations de publication

Date de publication:
01 Oct 2024
Historique:
received: 18 07 2024
accepted: 13 09 2024
medline: 2 10 2024
pubmed: 2 10 2024
entrez: 1 10 2024
Statut: epublish

Résumé

Metabolic reprogramming, a key mechanism regulating the growth and recurrence of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), still lacks effective clinical strategies for its integration into the precise screening of primary liver cancer. This study utilized ultra-high-performance liquid chromatography with quadrupole time-of-flight mass spectrometry to conduct a comprehensive, non-targeted metabolomics analysis, revealing significant upregulation of lipid metabolites such as phosphatidylcholine and lysophosphatidylcholine in patients with HCC and CCA, particularly within the glycerophospholipid metabolic pathway. Hematoxylin and eosin and immunohistochemical staining demonstrated marked upregulation of phospholipase A

Identifiants

DOI: 10.1186/s12944-024-02298-4 PMID: 39354487
pubmed: 39354487
doi: 10.1186/s12944-024-02298-4
pii: 10.1186/s12944-024-02298-4
doi:

Substances chimiques

Glycerophospholipids 0
Phosphatidylcholines 0
Lysophosphatidylcholines 0
Phospholipases A2 EC 3.1.1.4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

326

Informations de copyright

© 2024. The Author(s).

Références

Desjonqueres E, et al. Preneoplastic lesions in the liver: molecular insights and relevance for clinical practice. Liver Int. 2022;42(3):492–506.
doi: 10.1111/liv.15152 pubmed: 34982503
Calderaro J, et al. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma. Nat Commun. 2023;14(1):8290.
doi: 10.1038/s41467-023-43749-3 pubmed: 38092727 pmcid: 10719304
Yang F, et al. Metabolic reprogramming and its clinical implication for liver cancer. Hepatology. 2023;78(5):1602–24.
doi: 10.1097/HEP.0000000000000005 pubmed: 36626639
Raggi C, et al. Metabolic reprogramming in cholangiocarcinoma. J Hepatol. 2022;77(3):849–64.
doi: 10.1016/j.jhep.2022.04.038 pubmed: 35594992
Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473.
doi: 10.1126/science.aaw5473 pubmed: 32273439 pmcid: 7227780
Hu B, Lin JZ, Yang XB, Sang XT. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: a review. Cell Prolif. 2020;53(3):e12772.
doi: 10.1111/cpr.12772 pubmed: 32003505 pmcid: 7106960
Yang K, et al. The role of lipid metabolic reprogramming in tumor microenvironment. Theranostics. 2023;13(6):1774–808.
doi: 10.7150/thno.82920 pubmed: 37064872 pmcid: 10091885
Lin J, Rao D, Zhang M, Gao Q. Metabolic reprogramming in the tumor microenvironment of liver cancer. J Hematol Oncol. 2024;17(1):6.
doi: 10.1186/s13045-024-01527-8 pubmed: 38297372 pmcid: 10832230
Anwanwan D, et al. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188314.
doi: 10.1016/j.bbcan.2019.188314 pubmed: 31682895
Huang X, et al. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Autophagy. 2019;15(7):1258–79.
doi: 10.1080/15548627.2019.1580105 pubmed: 30786811 pmcid: 6613896
Zhao L, et al. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer. Cell Death Dis. 2022;13(4):378.
doi: 10.1038/s41419-022-04821-w pubmed: 35444235 pmcid: 9021207
Dang NH, et al. Targeted cancer therapeutics: biosynthetic and energetic pathways characterized by metabolomics and the interplay with key cancer regulatory factors. Curr Pharm Des. 2014;20(15):2637–47.
doi: 10.2174/13816128113199990489 pubmed: 23859615
Han J, Li Q, Chen Y, Yang Y. Recent Metabolomics Analysis in Tumor Metabolism Reprogramming. Front Mol Biosci. 2021;8:763902.
doi: 10.3389/fmolb.2021.763902 pubmed: 34901157 pmcid: 8660977
Hall Z, et al. Lipid remodeling in hepatocyte proliferation and hepatocellular carcinoma. Hepatology. 2021;73(3):1028–44.
doi: 10.1002/hep.31391 pubmed: 32460431
de Gauna Ruiz M, et al. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids. Hepatology. 2022;76(6):1617–33.
doi: 10.1002/hep.32344
Satriano L, et al. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol. 2019;16(12):748–66.
doi: 10.1038/s41575-019-0217-8 pubmed: 31666728
Luo Z, Eichinger KM, Zhang A, Li S. Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy. Cancer Lett. 2023;575:216396.
doi: 10.1016/j.canlet.2023.216396 pubmed: 37739209
Chen S, Duan H, Sun G. Reshaping immunometabolism in the tumour microenvironment to improve cancer immunotherapy. Biomed Pharmacother. 2023;164:114963.
doi: 10.1016/j.biopha.2023.114963 pubmed: 37269814
Li H, et al. MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis. Cancer Lett. 2021;519:161–71.
doi: 10.1016/j.canlet.2021.07.029 pubmed: 34303763
Zhang H, et al. Oleic acid-PPARγ-FABP4 loop fuels cholangiocarcinoma colonization in lymph node metastases microenvironment. Hepatology. 2024;80(1):69–86.
pubmed: 38377465
Tan SLW, et al. The altered lipidome of hepatocellular carcinoma. Semin Cancer Biol. 2022;86(Pt 3):445–56.
doi: 10.1016/j.semcancer.2022.02.004 pubmed: 35131480
Shalapour S, Karin M. Fatty acid-induced T cell loss greases liver carcinogenesis. Cell Metab. 2016;23(5):759–61.
doi: 10.1016/j.cmet.2016.04.018 pubmed: 27166937
Sonkar K, et al. Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer. NMR Biomed. 2019;32(10):e4112.
doi: 10.1002/nbm.4112 pubmed: 31184789 pmcid: 6803034
Law SH, et al. An updated review of lysophosphatidylcholine metabolism in human diseases. Int J Mol Sci. 2019;20(5):1149.
doi: 10.3390/ijms20051149 pubmed: 30845751 pmcid: 6429061
Vinciguerra M, et al. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN. J Hepatol. 2009;50(6):1132–41.
doi: 10.1016/j.jhep.2009.01.027 pubmed: 19398230
Lin CR, et al. Omega-3 polyunsaturated fatty acids suppress metastatic features of human cholangiocarcinoma cells by suppressing twist. J Nutr Biochem. 2019;74:108245.
doi: 10.1016/j.jnutbio.2019.108245 pubmed: 31678746
Yun BK, et al. Potential nutritional and metabolomic advantages of high fat oral supplementation in pancreatectomized pancreaticobiliary cancer patients. Nutrients. 2019;11(4):893.
doi: 10.3390/nu11040893 pubmed: 31010058 pmcid: 6521063
Lagal DJ, et al. Loss of PRDX6 aborts proliferative and migratory signaling in hepatocarcinoma cell lines. Antioxidants (Basel). 2023;12(6):1153.
doi: 10.3390/antiox12061153 pubmed: 37371884
Ashkar F, Wu J. E-Cadherin and its signaling pathways: a novel target of dietary components in modulating cell migration and proliferation. Trends Food Sci Technol. 2024;146:104398.
doi: 10.1016/j.tifs.2024.104398
Ambesi A, McKeown-Longo PJ. Anastellin, the angiostatic fibronectin peptide, is a selective inhibitor of lysophospholipid signaling. Mol Cancer Res. 2009;7(2):255–65.
doi: 10.1158/1541-7786.MCR-08-0195 pubmed: 19208746 pmcid: 2658630
Hou R, et al. Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma. Cell Rep. 2022;39(12):111000.
doi: 10.1016/j.celrep.2022.111000 pubmed: 35732130 pmcid: 9282716
Ferreira MT, et al. Cyclooxygenase inhibition alters proliferative, migratory, and invasive properties of human glioblastoma cells in vitro. Int J Mol Sci. 2021;22(9):4297.
doi: 10.3390/ijms22094297 pubmed: 33919029 pmcid: 8122446

Auteurs

Yanran Bi (Y)

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Imaging Diagnostic and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.
Clinical College of The Affiliated Central Hospital, School of Medcine, Lishui University, Lishui, 323000, China.
Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.

Xihui Ying (X)

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Imaging Diagnostic and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.
Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.

Wanbin Chen (W)

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Imaging Diagnostic and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.
Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.

Jiahao Wu (J)

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Imaging Diagnostic and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.
Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.

Chunli Kong (C)

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Imaging Diagnostic and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.
Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.

Weiming Hu (W)

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Imaging Diagnostic and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.
Clinical College of The Affiliated Central Hospital, School of Medcine, Lishui University, Lishui, 323000, China.
Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.

Shiji Fang (S)

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Imaging Diagnostic and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.
Clinical College of The Affiliated Central Hospital, School of Medcine, Lishui University, Lishui, 323000, China.
Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.

Junchao Yu (J)

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Imaging Diagnostic and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.
Clinical College of The Affiliated Central Hospital, School of Medcine, Lishui University, Lishui, 323000, China.
Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.

Mengqian Zhai (M)

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Imaging Diagnostic and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.
Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.

Chengli Jiang (C)

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Imaging Diagnostic and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.
Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.

Minjiang Chen (M)

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Imaging Diagnostic and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.
Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China.

Lin Shen (L)

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Imaging Diagnostic and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China. lin_shen168@wmu.edu.cn.
Clinical College of The Affiliated Central Hospital, School of Medcine, Lishui University, Lishui, 323000, China. lin_shen168@wmu.edu.cn.
Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China. lin_shen168@wmu.edu.cn.

Jiansong Ji (J)

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Imaging Diagnostic and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China. jjstcty@wmu.edu.cn.
Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China. jjstcty@wmu.edu.cn.

Jianfei Tu (J)

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Imaging Diagnostic and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China. jianfei1133@wmu.edu.cn.
Department of Interventional Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, No 289, Kuocang Road, Lishui, 323000, China. jianfei1133@wmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Glycerophospholipid-driven lipid metabolic...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Adénocarcinome › Cholangiocarcinome › Glycerophospholipid-driven lipid metabolic...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Carcinome hépatocellulaire › Glycerophospholipid-driven lipid metabolic...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Glycerophospholipid-driven lipid metabolic...
questionsmedicales.fr › Lipides › Lipides membranaires › Phospholipides › Glycérophosphate › Acides phosphatidiques › Glycérophospholipides › Glycerophospholipid-driven lipid metabolic...
questionsmedicales.fr › Métabolisme › Métabolisme lipidique › Glycerophospholipid-driven lipid metabolic...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Glycerophospholipid-driven lipid metabolic...
questionsmedicales.fr › Maladies de l'appareil digestif › Tumeurs de l'appareil digestif › Tumeurs des voies biliaires › Tumeurs des canaux biliaires › Glycerophospholipid-driven lipid metabolic...
questionsmedicales.fr › Disciplines des sciences naturelles › Chimie › Biochimie › Métabolomique › Glycerophospholipid-driven lipid metabolic...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Glycerophospholipid-driven lipid metabolic...
questionsmedicales.fr › Lipides › Lipides membranaires › Phospholipides › Glycérophosphate › Acides phosphatidiques › Glycérophospholipides › Phosphatidylcholines › Glycerophospholipid-driven lipid metabolic...
questionsmedicales.fr › Lipides › Lipides membranaires › Phospholipides › Glycérophosphate › Acides phosphatidiques › Lysophospholipides › Lysolécithine › Glycerophospholipid-driven lipid metabolic...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Glycerophospholipid-driven lipid metabolic...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Esterases › Carboxylic ester hydrolases › Phospholipases A › Phospholipases A2 › Glycerophospholipid-driven lipid metabolic...